Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Mar 12, 2013 4:37pm

320 Views

Post# 21118443

RE: RE: RE: RE: RE: AGM Summary from trt on I.V.

Don is scheduled to speak at the BioEurope conference in Barcelona at 9:15 AM (Barcelona time) tomorrow, which is about 12 hours from now. And the ACC conference wraps up tomorrow as well. After tomorrow, there is nothing that RVX has listed on their upcoming events page. The RVX team will probably be returning home soon now that their March madness of travels and conferences is over. It will be interesting to see what direction they now take: prolonged silence or some news. We will see.

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024